This trial is studying whether a combination of two immunotherapy drugs, nivolumab and ipilimumab, can help to shrink solid tumors in children and young adults.
- Ewing Sarcoma
- Relapsed Pediatric Solid Tumors
- Refractory Pediatric Solid Tumors
- Liver Cancer
- Wilms Tumor
2 Primary · 4 Secondary · Reporting Duration: 12 months
Side Effects for
Awards & Highlights
1 Treatment Group
1 of 1
42 Total Participants · 1 Treatment Group
Primary Treatment: Nivolumab · No Placebo Group · Phase 2
Who is running the clinical trial?
Age 1 - 39 · All Participants · 2 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Who else is applying?
What state do they live in?
What site did they apply to?
|Children's National Hospital||100.0%|
What portion of applicants met pre-screening criteria?
|Did not meet criteria||100.0%|
Frequently Asked Questions
Who is eligible to join this research project?
"This clinical trial is accepting 42 participants suffering from rhabdomyosarcoma, ranging in age between 1 and 39. Eligibility criteria includes the following: a Karnofsky score of at least 50% for those 16 or older, Lansky performance score of 60% or higher for minors under 16, full recovery from any prior chemotherapy treatments at least 21 days before study entry, two measurable/evaluable solid target lesions upon evaluation, one tumor available to receive cryoablation therapy and consent from either patient (if above legal age) or guardian/parent. Furthermore, histologically confirmed osteosarcoma, E" - Anonymous Online Contributor
What objectives are the scientists hoping to accomplish through this trial?
"This medical study's primary aim is to assess the occurrence and magnitude of treatment-related side effects using CTCAE v. 5 over a period of 12 months. Additionally, biomarkers associated with checkpoint inhibition will be observed in patient blood via flow cytometry at baseline and during the trial, alongside PROMIS® Pediatric Scale v1.0 Global Health 7+2 scores for health outcomes pre-cycle start and last visit, as well as Parent Proxy Scale v1.0 Global Health 7+2 ratings at all points mentioned previously." - Anonymous Online Contributor
Has the Food and Drug Administration officially certified Nivolumab for public use?
"Nivolumab's safety is rated as a 2 by our team at Power due to the fact that this Phase 2 trial has yielded data affirming it protection but not its efficacy." - Anonymous Online Contributor
Is it still possible to enroll in this clinical research project?
"According to clinicialtrials.gov, this clinical trial has been ongoing since February 18th 2022 and is actively searching for participants. The study was last updated on March 21st of the same year." - Anonymous Online Contributor
Does this exploration include geriatric participants?
"In order to be considered for this investigation, the patient must be below 40 years old. Currently, there are 575 studies accepting minors under 18 and 3327 studies enrolling seniors above 65." - Anonymous Online Contributor
How many participants have been enrolled in this experiment?
"Indeed, data from clinicaltrials.gov reveals that this experiment is currently recruiting patients. Initially released on February 18th 2022 and most recently updated on March 21st 2022, the study requires 42 participants to be recruited across 1 location." - Anonymous Online Contributor